LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Joint Statement on the Health Innovation Partnership Proposal

03/08/2020
POSITION PAPER

Joint Statement on the Health Innovation Partnership Proposal

Health industry sectors, representing pharmaceutical and medical technology companies (COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe) welcome the publication of the Partnership Proposal as a significant milestone towards a European Partnership for Health Innovation.

A future for collaborative research & development in Europe

The future partnership will showcase to researchers, patients, and citizens that Europe has the ambition to be a world-leader in collaborative research and development (R&D). It will pioneer the patient-centred integration of knowledge, technology and products to address the entire care continuum for the benefit of patients across Europe and beyond.

Investment in collaborative R&D can play a significant role in building health resilience, improving European health systems’ sustainability, addressing the needs of patients across Europe, and driving the region’s economic recovery from the COVID-19 crisis. The pandemic has also underlined the importance of having a large-scale partnership for health innovation to mobilise and coordinate public and private research efforts aimed at tackling global public health threats.

Insights into an ambitious and pioneering public-private proposal

The life-science sector partners and the European Commission describe the new partnership's objectives, deliverables, governance and operational model in the Partnership Proposal. While the proposal will be subject to further discussion, the document already gives an insight into the specific elements that will be addressed in the draft partnership legislation expected in Autumn 2020.

All partners are dedicated to developing new solutions for patients, healthcare professionals and systems, as well as their implementation in research and health practice in different socio-economic conditions across Europe. Impactful solutions for public health and sustainable healthcare systems have always been and will remain at the core of our industries’ mission. This endeavour will guide the work of scientists and researchers collaborating under the new health innovation partnership. The partners fully support the European Commission in its efforts to provide a harmonised set of rules for institutionalised partnerships while, at the same time, ensuring efficient processes and flexibility for crosssectorial collaboration.

Opening new spaces for impactful synergies

For a thriving European research ecosystem, this new partnership will create synergies and complement other features of the European research landscape, in particular with the EUAfrica Global Health Partnership, potential co-funded Partnerships on ‘Health and Care Systems Transformation’, the European Partnership for One Health/AMR and ‘Pandemic Preparedness and Societal Resilience’, and with the EU4Health Programme.

Download the file below to read the full Position Paper.

Joint Statement on the Health Innovation Partnership Proposal


Download
2020_08_H_PP_Health-Innovation-PPP-Proposal-Joint-StatementDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.